Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Robert McWhirter
Protech Home Medical CorpPTQ.VPAST TOP PICKMay 13, 2021
(A Top Pick May 29/20, Up 55%) Oxygen delivery. Recurring revenue model. Very strong outlook.
N/A
Stock price when the opinion was issued
$2.06
As of May 12, 2021. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
PAST TOP PICK
(A Top Pick May 27/20, Up 65%) They plan on changing their name and moving onto the Nasdaq. They fly under the radar but trade at an attractive valuation. He's sticking with this. It will continue to do well on the Nasdaq.
Bruce Campbell (2)Owned
biotechnologypharmaceutical
BUY
A US company that's consolidating in the medical market (home lifts, ventilators, oxygen, etc.). He continues to like it. It was a past pick and since they made an acquisition. The stock has increased, though not as much as he expected. He predicts the valuation will be pretty attractive. This could be a takeover target and it's firing on all cylinders.
Bruce Campbell (2)Owned
biotechnologypharmaceutical
TOP PICK
It continues to stay in this valuation range. They are in the home medical business. They operate in ten states and have 40 locations. It is a fragmented industry. They have 68% recurring revenue. They have a huge opportunity to consolidate. They can grow through valuation multiple growth and organically. (Analysts’ price target is $2.36)
Bruce Campbell (2)Owned
biotechnologypharmaceutical
TOP PICK
They are taking advantage of in-home health care during the pandemic. It trades at about a third of their peers, yet growth has been 20% per year. They focus on an area of the medical space that will get head winds from COVID. It will likely be taken out sometime later this year. Yield 0% (Analysts’ price target is $2.36)
Bruce Campbell (2)Owned
biotechnologypharmaceutical
BUY
This is one that a piece of their business benefits from COVID. Oxygen sales, sleep apnea, as people get released FROM COVID hospitalization, they can get onto home ventilators. He likes it. It was a past top pick.
Bruce Campbell (2)Owned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jan 30/19, Down 4%) He would have expected it to do more. He is quite confident going forward. He thinks they will get taken out within 18 months. Almost made it a top pick again.
Bruce Campbell (2)Owned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Dec 12/18, Up 41%) It continues to grow organically and by acquisition. It is very attractive at less than 8 times earnings, which are growing at 12-15% per year. It will either get recognized by the market or get taken out.
Bruce Campbell (2)Owned
biotechnologypharmaceutical
BUY
They've recently announced they had a cyber attack and lost $9 million but they should get most of it back. They'll be then able to go do more mergers and acquisitions after, which should be in September. The valuation is very attractive, and it should bounce up when they make the press release that they have recovered their funds.
Bruce Campbell (2)Owned
biotechnologypharmaceutical
BUY
In the U.S. healthcare business. They have transformed in the past year, raising profit margins and accounts receivable. They are highly profitable around 20%. Trades at less than 10x 2020's EBITDA. Management continues to execute, doing small acqusitions.
Bruce Campbell (2)Owned
biotechnologypharmaceutical
TOP PICK
They just released earnings this week and they have been turning their business around -- increasing margins and growing organically. Management owns about 18% of the shares and it trades at 5 times earnings. He thinks it could trade at twice that level. They are involved in patient home monitoring. Yield 0% (Analysts’ price target is $3.00)
Bruce Campbell (2)Owned
biotechnologypharmaceutical
